Herclov

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Herclov

Property Description
Active ingredient Valacyclovir Hydrochloride (Valaciclovir)
Form Oral Tablet
Pharmacological class Antiviral Drug (Purine Nucleoside Analog)
Common use Management of herpesvirus infections
Origin Synthetic Prodrug

What is Herclov and Its Antiviral Classification?

Herclov is a prescription medicine formulated as an oral tablet and is classified as a synthetic antiviral drug. The active component, Valacyclovir Hydrochloride (Valaciclovir), belongs to the class of purine nucleoside analogs. This compound is clinically recognized for its highly targeted action against viral pathogens and is specifically used to manage infections caused by the herpesvirus group, including common strains such as Herpes Simplex Virus and Varicella Zoster Virus. Herclov, as a branded product, represents a standard, single-ingredient formulation of Valacyclovir Hydrochloride typically prescribed for adult patient groups.

Composition: Why is Valacyclovir a "Prodrug"?

The defining feature of Valacyclovir Hydrochloride is its status as a prodrug, meaning it requires metabolic transformation inside the body to become fully active. The molecule is a synthetic L-valine ester derivative of the established antiviral, Acyclovir. This unique composition was engineered to confer significantly improved absorption. This enhanced delivery mechanism ensures a reliable amount of the active medicine reaches the bloodstream, which is critical for systemic treatment.

The General Purpose of Herclov

The general purpose of Herclov is to control the spread of active infections by halting the virus’s ability to multiply within the system. Once converted, the active Acyclovir acts selectively as a false nucleoside component within the infected cells, interfering directly with the viral replication process. By disrupting this essential function, the medication limits the overall activity and extent of the viral infection, thereby helping to alleviate discomfort and shorten the duration of the episode. This action is critical in scenarios such as managing an outbreak of shingles or controlling recurrent cold sores.

Regulatory References

  1. NIH Valacyclovir Monograph

What side effects are possible with Herclov?

Possible Side Effects and Safety Information

The safety profile of Herclov, which contains Valacyclovir, is formally documented in regulatory labeling according to the frequency and system-organ class affected. This section describes the officially listed spectrum of adverse reactions.

Frequency-Classified Adverse Reactions

The most frequently listed adverse reaction, classified as Very Common in official sources, is Headache. Common adverse reactions typically involve the gastrointestinal and nervous systems and include Nausea, Dizziness, Vomiting, and Diarrhea.

Reactions classified as Uncommon or Rare include events affecting the blood, skin, and nervous system, such as leucopenia, confusion, hallucinations, and rashes. These neurological effects are often noted as being generally reversible upon stopping the medicine.

Serious Adverse Reactions and Population Constraints

Official regulatory documents emphasize specific serious adverse reactions. These include Acute Renal Failure and severe Central Nervous System Effects (such as encephalopathy, convulsions, and coma). These more severe events are reported predominantly in patients with pre-existing renal impairment, the elderly, or those receiving doses higher than recommended for their kidney function.

Adequate fluid intake is a specific safety note in the labeling for patients at risk of dehydration, as it is critical for kidney function during treatment. A severe blood disorder, Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome (TTP/HUS), is also listed, particularly associated with prolonged high-dose use in severely immunocompromised individuals.

Overdose and Emergency Response

If there is any suspicion of an overdose involving Herclov, immediate medical attention is required. Contact a local poison control center or emergency services right away. Do not wait for symptoms to worsen.

Overdose of the active component in Herclov, which is chemically related to valacyclovir, is associated with a risk of central nervous system (CNS) effects and acute kidney injury. Symptoms of a potential overdose may include:

  • Neurological changes: Severe confusion, agitation, aggressive behavior, hallucinations (seeing or hearing things that are not there), feeling unsteady or shaky, and seizures.
  • Kidney-related issues: A significant decrease in the amount of urine, swelling of the hands, ankles, or lower legs, and unusual weakness or tiredness.
  • Gastrointestinal effects: Extreme tiredness, persistent upset stomach, or vomiting.

Individuals who have a pre-existing history of kidney problems, including reduced kidney function or those undergoing dialysis, and elderly patients are at a higher risk for serious adverse effects, including neurotoxicity, from elevated drug levels. In these populations, a lower dose is often medically necessary to prevent drug accumulation.

In all cases of suspected overdose, medical professionals will provide symptomatic and supportive care. Early intervention is crucial, as delayed onset of neurotoxicity may occur even after peak concentrations in the body. Hemodialysis is sometimes used in severe cases to help clear the medication from the body, particularly when kidney function is impaired.

Therapeutic Uses of Herclov

What Herclov treats: main uses and benefits

Herclov is an antiviral medication containing the active ingredient valacyclovir. It is primarily used to manage infections caused by the herpes simplex virus (HSV) and the varicella-zoster virus (VZV). The medication works by interfering with the replication process of the viral DNA, which helps the body's immune system control the infection.

Treatment of Shingles

Herclov is used to treat herpes zoster, commonly known as shingles. Shingles is caused by the reactivation of the varicella-zoster virus, the same virus responsible for chickenpox. In patients with shingles, the medication helps to:

  • Shorten the duration of viral shedding.
  • Accelerate the healing of skin lesions and crusting.
  • Reduce the intensity and duration of acute pain associated with the rash.

Management of Genital Herpes

The medication is used for the treatment and management of genital herpes caused by the herpes simplex virus. It is applied in two primary ways:

  • Treatment of outbreaks: It is used to treat initial episodes and recurrent outbreaks of genital herpes, helping to resolve sores more quickly.
  • Suppressive therapy: In individuals with frequent recurrences, daily use can help reduce the number of future symptomatic episodes.
  • Reduction of transmission: Chronic suppressive therapy can lower the risk of transmitting the virus to uninfected partners when combined with safer sex practices.

Treatment of Cold Sores

Herclov is used for the treatment of herpes labialis, commonly referred to as cold sores or fever blisters. When started at the first signs of a cold sore (such as tingling or itching), it can reduce the healing time and limit the severity of the lesion.

Treatment of Chickenpox

In certain cases, the medication is used to treat varicella (chickenpox) in children and adolescents. It is typically intended to reduce the severity of the illness and the number of cutaneous lesions when administered shortly after the onset of the rash.

Therapeutic Benefits

The primary benefit of Herclov is its ability to manage viral activity. While the medication does not cure viral infections—as the viruses remain dormant in the nerve cells—it significantly reduces the impact of the infection on daily life by decreasing symptoms, preventing complications, and improving the quality of life during and between outbreaks.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who can and cannot use Herclov? — Official Regulatory Information

Herclov (Valacyclovir) eligibility is strictly defined by regulatory documentation, primarily based on patient hypersensitivity, age, and organ function.

Eligibility scope Classification Restriction Detail
Contraindicated Absolute Prohibition Patients with known hypersensitivity to valacyclovir, acyclovir, or any component of the formulation.
Age-Related Approved/Not Established Adults (18 years) are generally approved. Use is not established for most indications in children under 12 years of age.
Conditional Use Requires Dose Adjustment Patients with renal impairment (kidney disease) and older adults (65 years) must have their dosage adjusted due to slower drug clearance.
Conditional Use Extreme Caution Patients with advanced HIV disease, bone marrow transplant, or renal transplant are at increased risk of serious side effects (TTP/HUS).
Reproductive Status Conditional/Restricted Use during pregnancy and lactation is generally restricted and requires assessment, as the active drug metabolite is found in breast milk.

Connection to the overall eligibility profile: The official regulatory documentation establishes that eligibility for Herclov is determined by an absolute hypersensitivity contraindication, followed by restrictions based on the patient’s renal function and immune status. These constraints define the population for whom the medicine is safe to use and whether a non-standard approach is mandated.

What should I know about interactions with other medicines?

The official documentation for Valacyclovir (Herclov) establishes the interaction profile based primarily on the renal elimination of its active metabolite, Acyclovir. No drug combinations are formally classified as contraindicated solely due to interaction risk.

Documented Pharmacokinetic Interactions

Interactions are documented with medicines that compete for the renal tubular secretion transport system, which is crucial for the elimination of Acyclovir. Co-administration with substances such as Probenecid and Cimetidine results in an increased systemic exposure of Acyclovir, evidenced by an increase in the Area Under the Curve (AUC) and a reduction in renal clearance. Taking both Probenecid and Cimetidine together is documented to result in an additive effect on Acyclovir exposure.

Co-administration with other nephrotoxic medicines (drugs that can impair kidney function) is cited in regulatory documents as a risk factor for Acute Renal Failure and potential Central Nervous System (CNS) reactions. This effect is driven by the reduced ability of the kidney to eliminate Acyclovir. Co-administration with Mycophenolate Mofetil (MMF) also results in increased plasma concentrations of Acyclovir.

Population-Specific Interaction Notes

The interaction severity in scenarios involving nephrotoxic drugs is officially noted to be greater for elderly patients and individuals with pre-existing impaired renal function due to their reduced baseline capacity for drug elimination.

Interactions with Food

The administration of Herclov with food does not affect the bioavailability of the active metabolite, Acyclovir, and is therefore not cited as a restriction.

Mechanism of Action

The drug's action is governed by a precise, multi-step molecular cascade, resulting in cessation of viral DNA synthesis, operating exclusively on actively multiplying viral cells. This mechanism achieves selective action via interference with the pathogen’s critical enzymatic processes.

The core of the drug’s function relies on its status as a prodrug, which requires rapid internal conversion into its active form, Acyclovir. The crucial subsequent step is selective activation, which happens almost entirely within infected cells because it requires a virus-specific enzyme, Viral Thymidine Kinase (TK), to initiate the process. This reliance on the viral enzyme results in the preferential concentration of the active drug where the pathogen is most active.

Once the active form, Acyclovir Triphosphate, is generated, it directly engages the Viral DNA Polymerase, the enzyme responsible for assembling new viral DNA. By acting as a false nucleoside and competing with the natural building blocks, the active drug is incorporated into the growing viral DNA strand. This incorporation results in DNA chain termination, physically halting the synthesis of the virus’s genetic material. The irreversible blockade of DNA synthesis creates a viral static state within the infected cells. This mechanistic consequence results in the intracellular arrest of viral multiplication, though the mechanism is structurally limited in its ability to affect the virus when it is in a dormant state within the nerve ganglia.

Dosage and Administration Information

Herclov is an antiviral medicine that must be administered orally, available as an oral tablet (500 mg and 1 gram) or an extemporaneously prepared suspension for patients unable to swallow the solid form. The correct dosage and duration are strictly determined by the specific infection being addressed. For the treatment of herpes zoster (shingles), the standard adult dose is 1 gram taken three times daily, typically for a seven-day course.

Therapy should be initiated at the earliest sign or symptom of the outbreak to comply with the official time-sensitive use protocol. For recurrent genital herpes, the usual adult dosage is 500 mg taken twice daily for a short-term course of three to five days. In contrast, the treatment of cold sores (herpes labialis) utilizes a high-dose, single-day regimen of 2 grams taken twice, approximately 12 hours apart. The tablets may be taken without regard to meals, but patients are advised to maintain adequate hydration.

A critical aspect of administration is dose modification for patients with impaired renal function. Since the medicine is primarily cleared by the kidneys, official instructions require a reduction in the total daily dose based on the patient's calculated creatinine clearance to avoid excessive systemic exposure. This requirement for adjustment is also relevant for older adults, whose renal status must be assessed before initiating therapy. For long-term suppressive use, the frequency is typically reduced to once daily.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Herclov

Evidence for the Treatment of Shingles (Herpes Zoster)

Research for Herclov's use in managing shingles relies mainly on short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time by examining various outcomes related to the acute infection. Researchers monitored the time until the shingles rash lesions fully healed and crusted over and tracked the duration and intensity of pain. Beyond the initial outbreak, studies monitored the incidence and duration of postherpetic neuralgia (PHN), which is a long-term nerve pain complication. The research has limited information on the outcomes for patients presenting late for treatment, because most studies required treatment initiation within 72 hours.


Evidence for Managing Recurrent Genital Herpes

The evidence for Herclov in managing recurrent genital herpes includes studies focusing on episodic treatment of active outbreaks and long-term suppressive therapy. For episodic treatment, short-term RCTs examined the time it took for active lesions to fully heal and the duration of pain. For suppressive therapy, long-term RCTs monitored the rate of clinical recurrence and the proportion of patients remaining outbreak-free over defined time intervals (up to a year). Evidence exploring clinical outcomes related to chronic recurrence prevention exists, primarily for genital herpes.


Evidence for Use Following Organ Transplantation

A specialized body of research has evaluated the use of Herclov in solid organ transplant recipients. This research primarily consists of RCTs and meta-analyses focused on prophylaxis for certain serious viral infections, particularly Cytomegalovirus (CMV) disease. Outcomes monitored the incidence of acute graft rejection and the incidence of opportunistic infections during the prophylaxis period. The results apply only to the specific populations studied and the defined high-dose prophylaxis periods.

Frequently Asked Questions (FAQ)

Common questions about Herclov (FAQ)

Q: Does Herclov cause drowsiness or make you tired?

A: Official product information notes that adverse reactions can include dizziness. Additionally, fatigue or tiredness has been reported in certain patient populations more frequently than with a placebo during studies. Adverse reactions such as dizziness or fatigue may affect the ability to perform complex tasks.

Q: Can I take Herclov if I'm already taking a common pain reliever like ibuprofen?

A: Regulatory documents advise caution when combining Herclov with medicines known as nephrotoxic drugs, which have the potential to impair kidney function. Common pain relievers like ibuprofen (a type of NSAID) may fall into this category and could increase the risk of kidney-related side effects. Regulatory guidelines emphasize that the use of such a combination should be discussed with a healthcare provider.

Q: Why do some people stop using Herclov?

A: In clinical studies, reasons for stopping the medicine often included common adverse reactions such as headache, nausea, and abdominal pain. Discontinuation may also occur if a patient experiences more severe, though less frequent, effects like Central Nervous System (CNS) reactions.

Q: Do I need a special diet while using Herclov?

A: Official labeling does not mandate a special diet for this medicine. However, the product information notes the importance of maintaining adequate hydration (drinking enough fluids) to help support kidney function and prevent potential kidney issues during treatment.

Q: What is the experience of patients who use Herclov long-term?

A: For indications requiring suppressive therapy, the drug is generally described as well-tolerated over extended periods. Nevertheless, official warnings indicate that patients on prolonged use must still be monitored, as serious side effects, including kidney issues and neurological toxicity, are potential risks that may be associated with prolonged use.

Q: Can Herclov be used in younger patients (under 18)?

A: Official documentation indicates that Herclov is approved for specific uses in patients aged 12 years and older. However, for most conditions, use in children under 12 is generally not established as supported by clinical evidence.

Q: Is Herclov available as a generic medicine?

A: Yes. Herclov is a brand name for the active ingredient, Valacyclovir Hydrochloride. This active component is widely available as a generic medicine, often simply referred to as valacyclovir.

Q: Can Herclov cause changes in mood or sleep?

A: Official product information lists certain Central Nervous System (CNS) effects, such as confusion and hallucinations. Additionally, adverse reactions have included reports of depression and difficulties with sleep (insomnia).

Q: How long can someone safely stay on Herclov?

A: Official labeling defines specific, short-term courses for treating active outbreaks (e.g., 3 to 7 days). For preventing recurrence, it is referred to as suppressive therapy, which is an ongoing, long-term option. However, official documents do not define a specific maximum duration or time limit for safe, continuous use.

Q: Is it okay to drive while taking Herclov?

A: Official labeling advises that if adverse effects such as dizziness or confusion occur, operating machinery or driving should be avoided.

Q: How quickly do people generally notice the effects of Herclov?

A: Clinical studies emphasize that treatment must be started at the first sign of an outbreak for best results. For conditions like shingles, official information indicates that the drug may begin to work by reducing pain within the first few days of starting therapy, though full lesion healing takes a longer duration.

Q: What happens if I miss a dose of Herclov?

A: Regulatory guidance indicates that if a dose is missed, it should be taken as soon as it is remembered. If it is almost time for the next dose, the missed dose should be skipped, and the patient should continue with the regular schedule.

Q: How long does Herclov stay in your system?

A: The active form of Herclov, Acyclovir, has an elimination half-life of approximately 2.5 to 3.3 hours in adults with normal kidney function. Most of the drug is eliminated from the body within 13 to 18 hours after the final dose.

Q: Does Herclov interact with common vitamin supplements?

A: Official labeling advises patients to notify their healthcare provider about all substances they are taking. This includes prescription medicines, over-the-counter drugs, herbal products, vitamins, and supplements, as these may have potential interactions with Herclov.

Q: Does Herclov have a 'Black Box Warning' from the FDA?

A: The current official prescribing information issued by the FDA for the active ingredient, Valacyclovir, does not contain a Boxed Warning. A Boxed Warning, sometimes referred to as a Black Box Warning, is used to highlight the most serious safety risks for a drug.

Q: Can I take other medicines for cold and flu while on Herclov?

A: The primary concern with Herclov is its clearance by the kidneys. It is important to be cautious about taking common cold and flu medicines that may contain ingredients classified as nephrotoxic (potentially harmful to the kidneys). It is important that any use of cold and flu medicines be discussed with a healthcare provider to assess potential interaction risks.

Q: Does Herclov have any potential interactions with alcohol?

A: Official guidance often cautions that combining the medicine with alcohol may potentially increase the risk of Central Nervous System side effects like dizziness or confusion. This is because both substances may affect the nervous system.

Q: Is Herclov addictive or habit-forming?

A: According to official drug labeling, the active component of Herclov, Valacyclovir, is not considered addictive or habit-forming. There are no reports of dependence or withdrawal symptoms associated with its use or discontinuation.

Q: What is the main safety classification of Herclov?

A: Herclov is classified as a prescription antiviral drug. In terms of reproductive safety, one official system categorized Valacyclovir as Pregnancy Category B3. Clinical data has also been collected to assess the risk of major birth defects, though no definite drug-related risk has been identified.

Q: Can Herclov affect liver function?

A: The medicine is primarily processed and eliminated by the kidneys. However, the regulatory documentation indicates that severe adverse reactions requiring medical attention can include signs of liver issues, such as the yellowing of the skin or eyes. These severe events are generally considered rare.

Q: Does Herclov interact with herbal remedies like St. John's Wort?

A: The official labeling advises patients to discuss the use of all substances, including herbs and supplements, with their healthcare provider. This ensures a comprehensive check for potential interactions, even if specific herbal remedies are not documented in the main product information.

Q: What is the purpose of the boxed warning on Herclov's label (if applicable)?

A: The current official prescribing information for Valacyclovir, the active component of Herclov, does not contain a Boxed Warning. The FDA uses this type of warning to highlight serious adverse reactions that may result in death or serious injury.

Q: Can I stop taking Herclov suddenly?

A: Official guidance advises patients to always finish the full course of therapy prescribed. Discontinuation should be discussed with a healthcare provider, especially before the full course of therapy is complete.

Q: What is the difference in side effects between Herclov and placebo in clinical trials?

A: Regulatory summaries, based on clinical trial data, show that common side effects such as fatigue and headache were reported at a higher rate in patients who received Herclov than in those who received an inactive placebo.

How should Herclov be stored and disposed of?

How to Store and Dispose of Herclov?

The storage and disposal of Herclov (valacyclovir hydrochloride) oral tablets must align strictly with official regulatory requirements to maintain product stability and ensure safety.


Storage Conditions

Herclov must be stored at Controlled Room Temperature, which is defined as 20°C to 25°C (68°F to 77°F), with permitted temperature excursions up to 30 C (86 F). The medicine must be kept protected from moisture and should be dispensed in a well-closed container. It is a mandatory requirement to store this medicine out of the sight and reach of children.


Disposal Instructions

Unused or expired Herclov must be disposed of properly according to local regulations. Regulatory guidelines instruct that the medicine must not be thrown away via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Herclov found in:

A-Z Index: